Details of the Drug
General Information of Drug (ID: DM72BSO)
Drug Name |
N-(2-benzyl),N-(1-methylpyrrol-2-ylmethyl)amine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Benzyl-(1-methyl-1H-pyrrol-2-ylmethyl)-amine; 73325-58-3; CHEMBL223300; [(1-methylpyrrol-2-yl)methyl]benzylamine; N-benzyl-1-(1-methyl-1H-pyrrol-2-yl)methanamine; pyrrole inhibitor 18; BAS 10796078; AC1M3ZOX; N-(2-benzyl),N-(1-methylpyrrol-2-ylmethyl)amine; SCHEMBL11567290; CTK6I2711; BDBM15593; MolPort-000-863-754; ZINC2868930; SBB010992; STK511232; BBL030414; 8940AE; AKOS000285009; MCULE-8292930001; ST063683; benzyl[(1-methylpyrrol-2-yl)methyl]amine; TR-044376; KB-250848; benzyl (1-methyl-1h-pyrrol-2-ylmethyl)amine
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 200.28 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||